Kexing Biopharm Co., Ltd. (SHA:688136)
China flag China · Delayed Price · Currency is CNY
46.81
+0.33 (0.71%)
Aug 8, 2025, 2:45 PM CST
0.71%
Market Cap9.32B
Revenue (ttm)1.40B
Net Income (ttm)44.65M
Shares Out199.38M
EPS (ttm)0.23
PE Ratio205.97
Forward PE84.96
Dividend0.08 (0.17%)
Ex-Dividend DateJun 12, 2025
Volume5,299,180
Average Volume9,595,822
Open46.11
Previous Close46.48
Day's Range45.60 - 47.37
52-Week Range13.67 - 63.99
Beta0.90
RSI46.52
Earnings DateAug 23, 2025

About Verve Therapeutics

Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon α1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1989
Employees 947
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688136
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.